Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. STKE, 2 January 2007
Vol. 2007, Issue 367, p. tw7
[DOI: 10.1126/stke.3672007tw7]

EDITORS' CHOICE

Immunology What's in a Vaccine?

Stephen Simpson

Science, AAAS, Washington, DC 20005, USA

After vaccination, the efficiency with which protective antibodies are produced often depends on the presence of an adjuvant, a substance that promotes activation of antibody-producing B cells. It has been anticipated that Toll-like receptors (TLRs) might be major players in mediating the effects of adjuvants. However, Gavin et al. now find that the known TLR pathways do not modulate B cell responses, and so adjuvants containing TLR ligands must depend on other properties. Such a revision to thinking about the effects of TLR on B cell responses will likely refocus current thinking about vaccine development.

A. L. Gavin, K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, D. Nemazee, Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314, 1936-1938 (2006). [Abstract] [Full Text]

Citation: S. Simpson, What's in a Vaccine? Sci. STKE 2007, tw7 (2007).


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882